Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
October 24 2023 - 8:00AM
Business Wire
Renowned Cardiothoracic Surgeon to Join Experienced Medical
Device Technology Leadership Team to Bring nsPFA to Cardiac
Surgery
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company
primarily focused on leveraging its novel and proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology for the
treatment of atrial fibrillation, today announced the appointment
of Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery.
“After working with the Pulse Biosciences’ team and
participating in preclinical studies using the nsPFA clamp for
cardiac ablation, it was immediately clear to me that nsPFA has the
potential to not only replace all other energy modalities in
cardiac ablation, including radiofrequency and cryo, but due to the
speed, safety, and ablation performance of the system, it has the
potential to significantly expand the number of patients we treat
in cardiac surgery,” said Dr. Niv Ad, Chief Science Officer,
Cardiac Surgery. “Because of this and how far along the Company is
in the development of a commercially viable system, I decided to
join this experienced team as it enters this next exciting phase of
bringing nsPFA from the lab to the clinic to make a positive impact
on patient lives and healthcare. I look forward to working
alongside this impressive team.”
Dr. Ad is a leading authority in surgical treatment of atrial
fibrillation, minimally invasive heart surgery and other advanced
heart surgery techniques and transcatheter therapies. Dr. Ad has
published more than 200 research articles in peer-reviewed
publications. He has led the development of national and
international clinical practice guidelines for the different
cardiovascular societies for ISMICS, AATS and STS, and serves on
multiple leadership positions and committees in the leading
cardiothoracic societies. He is the past president of The
International Society of Minimally Invasive Cardiothoracic and
Vascular Surgery (MICS), the leading entity for minimally invasive
procedures globally and he is the Editor in Chief of INNOVATIONS:
Technology and Techniques in Cardiothoracic and Vascular
Surgery.
“We are excited to have Dr. Ad join the Pulse Biosciences team.
His proven track record and expertise will play an integral role in
not only our clinical strategy and driving awareness of our
technology through scientific data dissemination, but also
contributing to the development of our product portfolio for
cardiac surgery,” said Kevin Danahy, Chief Executive Officer of
Pulse Biosciences. “We believe two of the top cardiothoracic
surgeons in the world, Dr. Niv Ad and Dr. Gansevoort ‘Gan’
Dunnington, committing to join our leadership team after firsthand
experience with nsPFA validates our scientific and engineering
expertise and is indicative of strong future market adoption of our
technology.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation and in a select few other markets
where nsPFA could have a profound positive impact on healthcare for
both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to statements concerning the effectiveness of
the Company’s nsPFA technology and CellFX System to non-thermally
clear cells while sparing adjacent non-cellular tissue, statements
concerning the Company’s expected product development efforts,
statements concerning customer adoption and future use of the
CellFX System to address a range of conditions such as atrial
fibrillation, and Pulse Biosciences’ expectations, whether stated
or implied, regarding whether the Company’s nsPFA technology will
become a disruptive treatment option for treating cardiac
arrhythmias and whether future clinical studies will show the
CellFX System is safe and effective to treat atrial fibrillation or
any other medical condition, and other future events. These
statements are not historical facts but rather are based on Pulse
Biosciences’ current expectations, estimates, and projections
regarding Pulse Biosciences’ business, operations and other similar
or related factors. Words such as “may,” “will,” “could,” “would,”
“should,” “anticipate,” “predict,” “potential,” “continue,”
“expects,” “intends,” “plans,” “projects,” “believes,” “estimates,”
and other similar or related expressions are used to identify these
forward-looking statements, although not all forward-looking
statements contain these words. You should not place undue reliance
on forward-looking statements because they involve known and
unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors,
including those described in Pulse Biosciences’ filings with the
Securities and Exchange Commission. Pulse Biosciences undertakes no
obligation to revise or update information in this release to
reflect events or circumstances in the future, even if new
information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231024037445/en/
Investor Contacts: Pulse Biosciences Kevin Danahy,
President and CEO 510.241.1077 IR@pulsebiosciences.com
or Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024